Leap Therapeutics Inc. Common Stock
Exchange: NASDAQ
Symbol: LPTX
SEC CIK: 0001509745
Phone: 617 252 4343
47 THORNDIKE STREET
SUITE B1-1
CAMBRIDGE MA 02142
CEO:
|
Price when page updated: 2.45 Date: 2023-12-01
Company Website:
www.leaptx.com
|
_Description: Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
IPO YEAR:
|
Sector:
Health Care
|
Industry:
Biotechnology: Biological Products (No Diagnostic Substances)
|
ADRTSO:
|
MarketCap:
62635264.00
|
Beta:
0.669842557857154
|
52 Week High:
4.17
|
52 Week Low:
1.33
|
52 Week Change:
0.3288288288288288
|
Short Interest:
|
Short Date:
|
Shares Outstanding:
88318454
|
Dividend Rate:
0
|
Dividend Yield:
N/A
|
ExDividend Date:
|
Latest EPS:
|
Latest EPS Date:
26 Oct 2022
|
Float:
0
|
return on Equity:
30.80%
|
Consensus EPS:
|
Number Of Estimates:
|
EPS Surprise Dollar:
|
Eps Surprise Percent:
|
EBITDA:
$197.278M
|
ttmEPS:
0
|
Revenue:
$1.128B
|
Gross Profit:
|
Cash:
|
Debt:
|
Institution Percent:
84.00%
|
Revenue Percent:
|
Revenue Per Employee:
|
Insider Percent:
2.20%
|
Return on Assets:
5.20%
|
Return on Capital:
|
Profit Margin:
24.80%
|
Price to Sales:
1.11
|
Price To Book:
1.08
|
Short Ratio:
4.01
|
PE Ratio:
0
|
Employees:
30
|
1Y Guesstimate
N/A:N/A:N/A
|
|
|
|
|
|
|
|
|
__The following are links to various summary and news pages for
__Leap Therapeutics Inc. Common Stock [ LPTX ].
__Note: Some Links might not have information for the company.
|
|
